Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown PD-0325901 + PF-04691502 urinary bladder cancer not applicable detail...
FGFR3 Y375C Ponatinib urinary bladder cancer sensitive detail...
FGFR3 Y375C Dovitinib urinary bladder cancer sensitive detail...
FGFR3 Y375C Cediranib urinary bladder cancer resistant detail...
FGFR3 Y375C Nintedanib urinary bladder cancer resistant detail...
FGFR3 Y375C Brivanib urinary bladder cancer no benefit detail...
FGFR3 S249C Ponatinib urinary bladder cancer sensitive detail...
FGFR3 S249C Dovitinib urinary bladder cancer sensitive detail...
FGFR3 S249C Cediranib urinary bladder cancer sensitive detail...
FGFR3 S249C Nintedanib urinary bladder cancer resistant detail...
FGFR3 S249C Brivanib urinary bladder cancer no benefit detail...
FGFR3 wild-type Ponatinib urinary bladder cancer resistant detail...
AKT1 E17K FGFR3 Y373C AZD5363 + AZD4547 urinary bladder cancer sensitive detail...
FGFR3-TACC3 R3Mab urinary bladder cancer sensitive detail...
FGFR3 act mut S-49076 urinary bladder cancer predicted - sensitive detail...
FGFR3 over exp SU5402 urinary bladder cancer sensitive detail...
FGFR3-TACC3 Selumetinib urinary bladder cancer no benefit detail...
FGFR3-TACC3 Pazopanib urinary bladder cancer sensitive detail...
FGFR3-TACC3 LY2874455 urinary bladder cancer sensitive detail...
FGFR3-TACC3 S-49076 urinary bladder cancer predicted - sensitive detail...
FGFR3-TACC3 Debio 1347 urinary bladder cancer sensitive detail...
FGFR3-BAIAP2L1 Debio 1347 urinary bladder cancer sensitive detail...
FGFR3 S249C Debio 1347 urinary bladder cancer sensitive detail...
FGFR3-TACC3 SU5402 urinary bladder cancer sensitive detail...
FGFR3-TACC3 AZ8010 urinary bladder cancer sensitive detail...
FGFR3-TACC3 Dovitinib urinary bladder cancer sensitive detail...
FGFR3-TACC3 FIIN-01 urinary bladder cancer sensitive detail...
FGFR3-TACC3 PRN1109 urinary bladder cancer sensitive detail...
FGFR3 S249C ASP5878 urinary bladder cancer sensitive detail...
FGFR3-TACC3 ASP5878 urinary bladder cancer sensitive detail...
FGFR3-BAIAP2L1 ASP5878 urinary bladder cancer sensitive detail...
HRAS mutant Metformin urinary bladder cancer sensitive detail...
PTEN del Metformin urinary bladder cancer sensitive detail...
Unknown unknown GSK2126458 urinary bladder cancer not applicable detail...
ERBB2 amp Afatinib urinary bladder cancer sensitive detail...
Unknown unknown AZD4547 + Cisplatin + Gemcitabine urinary bladder cancer not applicable detail...
FGFR3 mut FGFR3 over exp Dovitinib urinary bladder cancer sensitive detail...
FGFR3 over exp Dovitinib urinary bladder cancer sensitive detail...
Unknown unknown ASP5878 urinary bladder cancer not applicable detail...
ERBB2 S310F Afatinib urinary bladder cancer sensitive detail...
ERBB2 S310F Lapatinib urinary bladder cancer sensitive detail...
ERBB2 S310F Selumetinib urinary bladder cancer decreased response detail...
ERBB2 S653C Afatinib urinary bladder cancer sensitive detail...
ERBB2 S653C Lapatinib urinary bladder cancer sensitive detail...
ERBB2 S653C Selumetinib urinary bladder cancer decreased response detail...
ERBB2 D277H ERBB2 S310F Afatinib urinary bladder cancer sensitive detail...
ERBB2 D277H ERBB2 S310F Lapatinib urinary bladder cancer sensitive detail...
ERBB2 D277H ERBB2 S310F Selumetinib urinary bladder cancer decreased response detail...
FGFR3 over exp BGJ398 urinary bladder cancer sensitive detail...
FGFR3 over exp Sorafenib + BEZ235 urinary bladder cancer sensitive detail...
Unknown unknown OBP-801 urinary bladder cancer not applicable detail...
Unknown unknown Celecoxib urinary bladder cancer not applicable detail...
Unknown unknown Celecoxib + OBP-801 urinary bladder cancer not applicable detail...
FGFR3-BAIAP2L1 PD173074 urinary bladder cancer sensitive detail...
FGFR3-BAIAP2L1 AZD4547 urinary bladder cancer sensitive detail...
FGFR3-BAIAP2L1 BGJ398 urinary bladder cancer sensitive detail...
FGFR3-BAIAP2L1 Cediranib urinary bladder cancer sensitive detail...
FGFR3-BAIAP2L1 Dovitinib urinary bladder cancer sensitive detail...
FGFR3 mutant AZD4547 urinary bladder cancer sensitive detail...
FGFR3 fusion AZD4547 urinary bladder cancer sensitive detail...
FGFR3-TACC3 E7090 urinary bladder cancer sensitive detail...
HRAS G12V Binimetinib + Everolimus urinary bladder cancer sensitive detail...
HRAS G12V Everolimus + Selumetinib urinary bladder cancer sensitive detail...
KRAS mutant PF3644022 + PF-477736 urinary bladder cancer predicted - sensitive detail...
Unknown unknown Atezolizumab urinary bladder cancer no benefit detail...
Unknown unknown TAS-120 urinary bladder cancer not applicable detail...
PTEN N48I Pictilisib urinary bladder cancer decreased response detail...
Unknown unknown BMS-986205 + Nivolumab urinary bladder cancer not applicable detail...
ERBB2 mutant Neratinib urinary bladder cancer no benefit detail...
ERBB2 D277G ERBB2 S310F Neratinib urinary bladder cancer predicted - resistant detail...
ERBB2 D769Y Neratinib urinary bladder cancer predicted - resistant detail...
ERBB2 G292R Neratinib urinary bladder cancer predicted - resistant detail...
ERBB2 S310F Neratinib urinary bladder cancer no benefit detail...
ERBB2 S310Y Neratinib urinary bladder cancer no benefit detail...
ERBB2 V777L Neratinib urinary bladder cancer no benefit detail...
ERBB2 L755S ERBB2 R1153* ERBB2 V777L Neratinib urinary bladder cancer no benefit detail...
ERBB2 Y772_A775dup Neratinib urinary bladder cancer predicted - resistant detail...
FGFR3 K652E Derazantinib urinary bladder cancer sensitive detail...
FGFR3-TACC3 Derazantinib urinary bladder cancer sensitive detail...
FGFR3-BAIAP2L1 Derazantinib urinary bladder cancer sensitive detail...
Unknown unknown Camrelizumab urinary bladder cancer not applicable detail...
Unknown unknown MPT0L145 urinary bladder cancer not applicable detail...
Unknown unknown BC-819 + BCG urinary bladder cancer not applicable detail...
Unknown unknown CG0070 urinary bladder cancer not applicable detail...
ERBB2 amp Pertuzumab + Trastuzumab urinary bladder cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab urinary bladder cancer predicted - sensitive detail...
FGFR3-TACC3 ODM-203 urinary bladder cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00959868 Phase I OGX-427 A Study for Treatment of Superficial Bladder Cancer Using OGX-427 Unknown status
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01738815 Phase I Valproic acid Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer Unknown status
NCT01928394 Phase Ib/II Ipilimumab Nivolumab A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Active, not recruiting
NCT02030067 Phase Ib/II RX-3117 Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies Active, not recruiting
NCT02043665 Phase I coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Active, not recruiting
NCT02091141 Phase II Erlotinib Alectinib Vemurafenib + Cobimetinib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Recruiting
NCT02177695 Phase II Gemcitabine + Cisplatin Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Recruiting
NCT02323191 Phase I Atezolizumab LY3022855 A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors Recruiting
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02351739 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer Active, not recruiting
NCT02360618 Phase II Metformin + Simvastatin Metformin and Simvastatin Use in Bladder Cancer Unknown status
NCT02365818 Phase II CG0070 Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure Completed
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Completed
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT02529553 Phase I LY3076226 A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Completed
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02546661 Phase I AZD4547 Durvalumab Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer Recruiting
NCT02605863 Phase II Enzalutamide Enzalutamide for Bladder Cancer Chemoprevention Terminated
NCT02643303 Phase Ib/II MEDI4736 + poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02646319 Phase II Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Active, not recruiting
NCT02655822 Phase I Atezolizumab CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02675829 Phase II trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Active, not recruiting
NCT02753309 Phase 0 Sirolimus A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer Recruiting
NCT02808143 Phase I BCG solution + Pembrolizumab Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer Recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Recruiting
NCT02922764 Phase I RGX-104 Nivolumab + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT03023319 Phase I Bosutinib + Pemetrexed Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting
NCT03224182 Phase III Apaziquone A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT Active, not recruiting
NCT03294304 Phase II Cisplatin + Gemcitabine + Nivolumab Nivolumab, Gemcitabine, and Cisplatin in Treatment of Bladder Cancer (MIBC) Undergoing Cystectomy Recruiting
NCT03298958 Phase III Sirolimus Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer Recruiting
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Recruiting
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Recruiting
NCT03333616 Phase II Nivolumab + Ipilimumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03519256 Phase II BMS-986205 + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + BMS-986205 + Nivolumab A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Recruiting
NCT03661320 Phase III Cisplatin + Gemcitabine + Nivolumab Gemcitabine + Cisplatin BMS-986205 + Cisplatin + Gemcitabine + Nivolumab A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC Recruiting
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 FOLFIRI + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Not yet recruiting